NASDAQ : PTCT
PTC Therapeutics, Inc. — Key statistics
Healthcare · Biotechnology · United States
Last price 64.46 USD (Oct 29, 2026, 4:00 PM EDT) · Market cap 5.38B
Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports
Key statistics
Valuation
| Measure | Value |
|---|
| Market Cap | 5.01B |
| Enterprise Value | 5.82B |
Dates
| Measure | Value |
|---|
| Earnings Date | Oct 29, 2026 |
| Ex-Dividend Date | n/a |
Shares
| Measure | Value |
|---|
| Current Share Class | 83.54M |
| Shares Outstanding | 83.54M |
| Shares Change (YoY) | -1.99% |
| Shares Change (QoQ) | -9.28% |
| Owned by Insiders (%) | 2.38% |
| Owned by Institutions (%) | 113.49% |
| Float | 73.77M |
Ratios
| Measure | Value |
|---|
| PE Ratio | n/a |
| Forward PE | 40.12 |
| PS Ratio | 4.34 |
| Forward PS | 3.73 |
| PB Ratio | n/a |
| P/TBV Ratio | n/a |
| P/FCF Ratio | 2,423.88 |
| P/OCF Ratio | 477.75 |
| PEG Ratio | n/a |
Evratios
| Measure | Value |
|---|
| EV / Earnings | n/a |
| EV / Sales | 5.04 |
| EV / EBITDA | 18.81 |
| EV / EBIT | 23.43 |
| EV / FCF | 2,817.55 |
Financialposition
| Measure | Value |
|---|
| Current Ratio | 3.27 |
| Quick Ratio | 3.05 |
| Debt / Equity | n/a |
| Debt / EBITDA | 8.89 |
| Debt / FCF | 1,423.14 |
| Interest Coverage | 1.25 |
Financialefficiency
| Measure | Value |
|---|
| Return on Equity (ROE) | n/a |
| Return on Assets (ROA) | 5.31% |
| Return on Invested Capital (ROIC) | 10.12% |
| Return on Capital Employed (ROCE) | 10.22% |
| Weighted Average Cost of Capital (WACC) | 6.43% |
| Revenue Per Employee | $1.17M |
| Profits Per Employee | -$106,933 |
| Employee Count | 991 |
| Asset Turnover | 0.39 |
| Inventory Turnover | 6.39 |
Taxes
| Measure | Value |
|---|
| Income Tax | 20.88M |
| Effective Tax Rate | n/a |
Stockprice
| Measure | Value |
|---|
| Beta (5Y) | 0.51 |
| 52-Week Price Change | -10.96% |
| 50-Day Moving Average | 65.36 |
| 200-Day Moving Average | 70.67 |
| Relative Strength Index (RSI) | 41.54 |
| Average Volume (20 Days) | 1,086,296 |
Shortselling
| Measure | Value |
|---|
| Short Interest | 8.30M |
| Short Previous Month | 9.17M |
| Short % of Shares Out | 9.94% |
| Short % of Float | 11.25% |
| Short Ratio (days to cover) | 6.38 |
Incomestatement
| Measure | Value |
|---|
| Revenue | 1.16B |
| Gross Profit | 637.69M |
| Operating Income | 248.55M |
| Pretax Income | -85.09M |
| Net Income | -105.97M |
| EBITDA | 309.56M |
| EBIT | 248.55M |
| Loss Per Share | -$1.28 |
Balancesheet
| Measure | Value |
|---|
| Cash & Cash Equivalents | 2.13B |
| Total Debt | 2.94B |
| Net Cash | -813.72M |
| Net Cash Per Share | -$9.74 |
| Equity (Book Value) | -191.21M |
| Book Value Per Share | -2.29 |
| Working Capital | 1.76B |
Cashflow
| Measure | Value |
|---|
| Operating Cash Flow | 10.49M |
| Capital Expenditures | -8.42M |
| Depreciation & Amortization | 61.01M |
| Net Borrowing | 131.47M |
| Free Cash Flow | 2.07M |
| FCF Per Share | $0.02 |
Margins
| Measure | Value |
|---|
| Gross Margin | 55.18% |
| Operating Margin | 21.51% |
| Pretax Margin | -7.36% |
| Profit Margin | -9.17% |
| EBITDA Margin | 26.79% |
| EBIT Margin | 21.51% |
| FCF Margin | 0.18% |
Dividends
| Measure | Value |
|---|
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| FCF Payout Ratio | n/a |
| Buyback Yield | 1.99% |
| Shareholder Yield | n/a |
| Earnings Yield | -2.13% |
| FCF Yield | 0.04% |
Analystforecasts
| Measure | Value |
|---|
| Price Target | $100.40 |
| Price Target Difference | 67.42% |
| Analyst Consensus | Buy |
| Analyst Count | 15 |
| Revenue Growth Forecast (3Y) | -2.22% |
| EPS Growth Forecast (3Y) | -19.85% |
Stocksplits
| Measure | Value |
|---|
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
| Measure | Value |
|---|
| Altman Z-Score | 1.04 |
| Piotroski F-Score | 4 |
Fairvalue
| Measure | Value |
|---|
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |